Queries for Author

Journal: British Journal of Sports Medicine
Paper: sm51193
Title: Is tendon pathology a continuum? A pathology model to explain the clinical presentation of load-induced tendinopathy

The proof of your manuscript appears on the following page(s). Please note that this is a galley proof and the layout of the article may change before publication. Please read the manuscript carefully, checking for accuracy, verifying the reference order and double-checking figures and tables. When reviewing your page proof please keep in mind that a professional copyeditor edited your manuscript to comply with the style requirements of the journal. This is not an opportunity to alter, amend or revise your paper; it is intended to be for correction purposes only.

During the preparation of your manuscript for publication, the questions listed below have arisen (the query number can also be found in the gutter close to the text it refers to). Please attend to these matters and return the answers to these questions when you return your corrections.

Please note, we will not be able to proceed with your article and publish it in print if these queries have not been addressed.

<table>
<thead>
<tr>
<th>Query Reference</th>
<th>Query</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Please supply caption for figure 1</td>
</tr>
<tr>
<td>2</td>
<td>Is Table 1 reproduced from ref. 24?</td>
</tr>
<tr>
<td>3</td>
<td>References 28 and 29 were duplicates. I have deleted ref. 29 and renumbered following references accordingly. Please check that no errors have been introduced.</td>
</tr>
<tr>
<td>4</td>
<td>Please provide full form of ACL</td>
</tr>
<tr>
<td>5</td>
<td>Fredburg et al (originally ref. 80, now ref. 79) is not cited – please add a citation or remove from the list</td>
</tr>
<tr>
<td>6</td>
<td>Please provide an Online First publication date for ref. 15</td>
</tr>
</tbody>
</table>

If you are happy with the proof as it stands, please email to confirm this. Changes that do not require a copy of the proof can be sent by email (please be as specific as possible).
Email: sueeclements@hotmail.co.uk

If you have any changes that cannot be described easily in an email, please mark them clearly on the proof and email a scan of the changes by replying to the eProof email or by fax: +44 (0)1932 348345.
Is tendon pathology a continuum? A pathology model to explain the clinical presentation of load-induced tendinopathy

J L Cook,1 C R Purdam2

ABSTRACT

Overuse tendinopathy is problematic to manage clinically. People of different ages with tendons under diverse loads present with varying degrees of pain, irritability, and capacity to function. Recovery is similarly variable; some tendons recover with simple interventions, some remain resistant to all treatments.

The pathology of tendinopathy has been described as degenerative or failed healing. Neither of these descriptions fully explains the heterogeneity of presentation. This review proposes, and provides evidence for, a continuum of pathology. This model of pathology allows rational placement of treatments along the continuum.

A new model of tendinopathy and thoughtful treatment implementation may improve outcomes for those with tendinopathy. This model is presented for evaluation by clinicians and researchers.

Overuse tendon injury (tendinopathy) occurs in loaded tendons of the upper and lower limb and results in pain, decreased exercise tolerance of the tendon and a reduction in function. Characteristic changes occur in tendon structure, resulting in a tendon that is less capable of sustaining repeated tensile load.

Tendon injury can occur in the mid-tendon, as in the Achilles tendon; however, most tendon pathology and pain arise at the tendon attachment to bone, such as the patellar tendon, medial and lateral elbow tendon and tendons of the groin. While the mid-tendon and the insertion are morphologically different in the normal state, the onset of pathology induces cell matrix changes that are indistinguishable; that is, the pathology appears to be the same.1 Despite a similar pathology, it has been shown in the Achilles that exercise specific for insertional or mid-tendon tendinopathy provides improved clinical outcomes, probably a reflection of the loading profiles in different parts of the tendon.2,3

Load has been shown to be both anabolic and catabolic for tendons.4 Repetitive energy storage and release and excessive compression appear to be key factors in the onset of tendinopathy. The amount of load (volume, intensity, frequency) that induces pathology is not clear; however, sufficient time between loadings to allow a tendon to respond to load appears important. Therefore volume (hours) and frequency (sessions per day or week) of intense load may be critical in the capacity of both normal and pathological tendons to tolerate load.5 Although load is a major patho-aetiological component, it is almost certainly modulated by an interaction between intrinsic factors such as genes, age, circulating and local cytokine production, sex, biomechanics and body composition.

Although loading history and individual factors may influence the onset and amount of tendon pathology, these are not generally considered when developing a treatment plan for painful tendons. Treatment for a first-time presentation of tendinopathy in a young athlete is often the same as that offered to a postmenopausal woman with chronic tendinopathy. The model proposed in this paper hypothesises that the pathology and the response to treatment are different in these presentations, and that interventions should be tailored to the pathology. Applying a single intervention to all presentations of tendinopathy is unlikely to be efficacious in every case.

This paper will examine existing concepts of tendinopathy and then present a model for the pathological process in tendon that collates existing knowledge. The model will be based on evidence from clinical and basic science studies in humans to demonstrate its validity.

EXISTING TENDON PATHOLOGY CONCEPTS

At least three states of tendon pathology have been described to date. Following the demise of a primary inflammatory model, tendinopathy was considered to be degenerative. Degenerative tendinopathy is described variably; pathological terms such as hypoxic degeneration, hyaline degeneration and mucoid degeneration are used, all of which suggest non-reparative, end-stage pathology.6 The key features of degenerative pathology centre on irreversible, degenerative cell changes and disintegration of the matrix.

Other authors have suggested that injured tendon is in a healing phase, with active cells and increased protein production, but with disorganisation of the matrix and neovascularisation. This has been called failed healing7 or angiofibroblastic hyperplasia.8

Failed healing and degeneration have been associated with chronic overload, but pathology has also been described when a tendon is unloaded (stress-shielded). Unloading a tendon induces cell and matrix change similar to that seen in an overloaded state9 and decreases the mechanical integrity of the tendon.10 In animals, this state has been shown to be mostly reversible11; however, few human studies have been conducted and tendon unloading will not be considered further in this paper.
Despite these varied descriptions of tendon pathology, the possibility that these may be linked in a continuum has received limited consideration. If a model of pathology can be developed that is continually evaluated and modified in the light of research findings, a better understanding of tendon pathology, treatment and prevention is possible.

A NEW MODEL OF TENDON PATHOLOGY

We propose that there is a continuum of tendon pathology that has three stages: reactive tendinopathy, tendon dysrepair (failed healing) and degenerative tendinopathy (fig 1). The model is described for convenience in three distinct stages; however, as it is a continuum, there is continuity between stages.

Adding or removing load is the primary stimulus that drives the tendon forward or back along the continuum, especially in the early stages. Within the constraints of recovery proposed in the model, reducing load may allow the tendon to return to a previous level of structure and capacity within the continuum.

What are the pathological, imaging and clinical manifestations at each stage?

1. Reactive tendinopathy

It is proposed that reactive tendinopathy, a non-inflammatory proliferative response in the cell and matrix, occurs with acute tensile or compressive overload. This results in a short-term adaptive and relatively homogeneous thickening of a portion of the tendon that will either reduce stress (force/unit area) by increasing cross-sectional area or allow adaptation to compression. This differs from normal tendon adaptation to tensile load, which generally occurs through tendon stiffening with little change in thickness.

Clinically, reactive tendinopathy results from acute overload, usually a burst of unaccustomed physical activity. Reactive tendinopathy can also be seen clearly after a direct blow such as falling directly onto the patellar tendon. This non-tensile, and only transiently compressive, load induces considerable reaction within the tendon cell and matrix.

Evidence that reactive tendinopathy occurs in response to overload is fairly strong from in-vitro work. There is a homogeneous, non-inflammatory cell response to load that leads to metaplastic change in the cells and cell proliferation. Tendon cells become more chondroid in shape, with more cytoplasmic organelles for increased protein production. The primary proteins are large proteoglycans, and this results in matrix change due to an increase in bound water associated with these proteoglycans. Collagen integrity is mostly maintained, although there can be some longitudinal separation, and there is no change in neurovascular structures.

These initial changes in ground substance in reactive tendinopathy may occur because quick adaptation is necessary until longer-term change in either structure or mechanical properties (true adaptation) happens. The quick response is possible as larger proteoglycans associated with tendinopathy (aggrecan and versican) and some glycoproteins (hyaluronan) can be upregulated in a timespan varying from minutes to a few days, much more quickly than the small proteoglycans of normal tendon (20 days).

Thus, reactive response is a short-term adaptation to overload that thickens the tendon, reduces stress and increases stiffness. The tendon has the potential to revert to normal if the overload is sufficiently reduced or if there is sufficient time between loading sessions.

Imaging

The tendon is swollen in a fusiform manner; the diameter is increased on both magnetic resonance imaging (MRI) and ultrasound (US) scans. Ultrasound shows reflection from intact collagen fascicles, with diffuse hypoechogenicity occurring between intact collagen structures. Magnetic resonance imaging will show minimal or no increased signal at this stage. The change in imaging appearance is mainly derived from the increase in bound water within the proteoglycans (fig 2).

Clinical

Reactive tendinopathy is seen clinically in an acutely overloaded tendon and is more common in a younger person. For example, a young jumping athlete who dramatically increases the number of jumping/landing repetitions a week may develop patellar tendon swelling and pain.

Tendons chronically exposed to low levels of load (e.g. in the detrained athlete returning from illness or injury, or a sedentary person) may also be vulnerable to this stage of tendinopathy when exposed to moderate increase in load. In addition it may occur as a result of direct trauma to tendon, to which the Achilles, patellar and elbow tendons are particularly exposed.

2. Tendon dysrepair

Tendon dysrepair describes the attempt at tendon healing, similar to reactive tendinopathy but with greater matrix breakdown. There is an overall increase in number of cells, which are mainly chondrocytic, as well as some myofibroblasts, resulting in a marked increase in protein production (proteoglycan and collagen). The increase in proteoglycans results in separation of the collagen and disorganisation of the matrix. The changes are somewhat more focal and matrix changes more varied than in the reactive stage. There may be an increase in vascularity and associated neuronal ingrowth.
3. Degenerative tendinopathy

This stage is clearly described in the literature, with progression of both matrix and cell changes. Areas of cell death due to apoptosis, trauma or tenocyte exhaustion are apparent. As a result, areas of acellularity have been described, and large areas of the matrix are disordered and filled with vessels, matrix breakdown products and little collagen. There is little capacity for reversibility of pathological changes at this stage. There is considerable heterogeneity of the matrix in these tendons, with islands of degenerative pathology interspersed between other stages of pathology and normal tendon.

Imaging

The imaging changes reflect increased matrix disorganisation, and these tendons are swollen, with increasing evidence of collagen disorganisation. On US there is some discontinuity of collagen fascicle and small focal areas of hypoechogenicity. The increase in vascularity may be evident on colour or power Doppler, and techniques to enhance vascularity (heat, exercise, hanging the limb) (personal communication, Cormick, 2008) may show a greater number of vessels. On MRI the tendon is swollen and there is increased signal within the tendon.

Clinical

This stage is primarily seen in the older person, but is seen in a younger person or elite athlete with a chronically overloaded tendon. The classic presentation is a middle-aged, recreational athlete with focal Achilles tendon swelling and pain. The tendon can have one or more focal nodular areas with or without general thickening. Individuals with degenerative changes often have a history of repeated bouts of tendon pain, often resolving but returning as the tendon load changes. Degenerative tendinopathy, if extensive enough, or if the tendon is placed under high load, can rupture, consistent with 97% of tendons that rupture having degenerative change.

EVIDENCE TO SUPPORT THIS MODEL

As longitudinal monitoring of histopathological change in humans is ethically difficult, the stages and progressions suggested in this model have been derived from integrating evidence from cross-sectional studies and supported by findings in animal models. Limited weight has been placed on outcomes in animal studies, as animal tendons do not directly translate to human tendinopathy. Longitudinal imaging studies in humans allow tracking of tendon change over time, and these demonstrate that some transition up and down the proposed pathology model occurs. Finally, limited evidence is available from clinical studies.

The concepts embedded in this model are strikingly similar to those reported for articular cartilage pathology. In osteoarthritis Pollard et al proposed a continuum from a reversible stage through to advanced osteoarthritis (table 1). The initial response centred on reversible proteoglycan upregulation, initial swelling and cellular upregulation, through to the latter stages of irreversible heterogeneous tissue change including cell and cartilage degeneration and erosion and subchondral bone remodelling.

Histopathological studies

Evaluation of human asymptomatic tendons demonstrated that cell change was always present when matrix change became apparent. Additionally, matrix change was primarily in ground substance, followed by collagen, and then (theoretically but not demonstrated) in vascularity. This provides evidence for the progression from normal to reactive response and tendon dysrepair; however, this study did not examine tendons that would be classified as degenerative. Although not considered a good model for human overuse tendinopathy, animal studies support these findings. Scott et al reported similar progression in pathology in overloaded rat supraspinatus tendons. Degenerative tendinopathy has been extensively described, but the transition from dysrepair has not been demonstrated.
This supports the viability of a transition from reactive change back to normal of the reactive response to load proposed in this model. This is the earliest form increase volume (circumference) and water (either bound as things: tendon response is rapid, and tendon response is to

**Table 1 Stages of osteoarthritis**

<table>
<thead>
<tr>
<th>Feature</th>
<th>Reversible injury</th>
<th>Osteoarthritis</th>
<th>Ageing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cartilage mass</td>
<td>Hypertrophy</td>
<td>Hypertrophy, erosion</td>
<td>No Change</td>
</tr>
<tr>
<td>Cartilage topographic distribution</td>
<td>Focal</td>
<td>Focal, Heterogeneous</td>
<td>General, all layers</td>
</tr>
<tr>
<td>Cartilage water</td>
<td>Oedema</td>
<td>Oedema</td>
<td>Dehydration</td>
</tr>
<tr>
<td>Cartilage collagen</td>
<td>Reversible</td>
<td>Degradation</td>
<td>Increased advanced glycation end products</td>
</tr>
<tr>
<td>Cartilage proteoglycan</td>
<td>Reversible depletion</td>
<td>Irreversible depletion</td>
<td>Reduced synthesis</td>
</tr>
<tr>
<td>Cartilage matrix degeneration products</td>
<td>Resorption</td>
<td>Accumulative, collagen, proteoglycan</td>
<td>Accumulative: oxidation, Glycation, amyloid</td>
</tr>
<tr>
<td>Cell activity</td>
<td>Reversibly increased activity and proliferation</td>
<td>Increased activity and proliferation</td>
<td>Reduced</td>
</tr>
<tr>
<td>Synovium</td>
<td>Mid focal superficial inflammation</td>
<td>Mid focal superficial inflammation</td>
<td>Atrophy</td>
</tr>
<tr>
<td>Bone</td>
<td>No Change</td>
<td>Subchondral remodelling</td>
<td>Osteopenia</td>
</tr>
</tbody>
</table>

PLACING CLINICAL TREATMENTS IN THE PATHOLOGY MODEL

Deciding where a tendon is in the pathological spectrum

For ease of use clinically, we have divided the pathology into two clear groups: reactive/early tendon dysrepair and late tendon dysrepair/degenerative. This will allow most clinical tendon presentations to be clearly placed in one of the two categories based on clinical assessment.

Clinical and imaging features allow a tendon to be placed in one of these two categories. An older person with a thick nodular tendon is likely to have a degenerative tendon; conversely, a young athlete after acute overload with a fusiform swelling of the tendon will probably have a reactive tendinopathy. There are, however, tendons in which it may be clinically difficult to stage the pathology, and in these tendons imaging may give vital clues. If the tendon is generally swollen and mildly hypoechoic or has small focal hypoechoic areas (one or several) with no or minimal vascular changes, this indicates reactive/early tendon dysrepair (fig 2). Tendons with large discrete areas of hypoechoogenicity, multiple vessels and more focal swelling will be in the late tendon dysrepair/degenerative category (fig 3).

This division of a continuum into two categories allows us to have a nominal threshold beyond which tendons will not fully return to normal structure. Cell dysfunction or death that compromises matrix protein production and/or the inability of the matrix to regain structural integrity results in a tendon incapable of full repair. It has been demonstrated that even after improvement in Achilles tendon pain and tendon structure and vascularity after an eccentric exercise programme, the tendon remains thicker than normal for several years.

**PLACING PAIN IN THIS MODEL OF TENDINOPATHY**

Pain can occur at any point in this pathological model, supporting the well-known dissociation between pain and pathology in tendinopathy. Even tendons that appear normal on imaging can be painful. Conversely, two-thirds of tendons degenerative enough to rupture have been reported to be pain-free before rupture.

The source of pain has been associated with neurovascular ingrowth, seen in this model at the late tendon dysrepair/degenerative phase. However, the fact that tendons can be painful or pain-free anywhere in this model suggests another or supplementary cause of pain that has so far proved elusive. The

Reactive to dysrepair

In a group of young athletes at risk of tendon overload and pathology there was a subgroup with microhypoechoic areas on US. This may represent a transition from reactive to tendon dysrepair, where small islands of the tendon develop collagen disorganisation. There is little evidence of reversal of this transition in the longitudinal studies to date.

Dysrepair to degenerative tendinopathy

This transition is not clearly demonstrated in the literature, as they are both considered abnormal and are not often identified as separate entities. Imaging evaluation of highly loaded patellar tendons in jumping athletes demonstrate that they primarily transition towards abnormality and pain that is more apparent in adults than in adolescents.

Clinical studies

The cumulative effect of load on a tendon has been clearly demonstrated when the tendon health of athletes who placed high loads on their Achilles tendons in early adulthood was later evaluated. Previous elite athletes had a higher cumulative incidence of tendinopathy and rupture than age-matched controls. As rupture represents end-stage degenerative tendinopathy, the higher rupture rates support high chronic load as an important factor in tendon pathology. This also supports the non-reversible nature of degenerative pathology, as these older ex-athletes had not spontaneously recovered tendon health.

The inability of a tendon to recover once it reaches the degenerative stage is supported by studies that have examined tendons many years after injury or rupture. Although the tendons may improve their function, they do not appear to return to normal size or morphology. Several studies have shown that large hypoechoic areas do not change, and similarly tendons used for ACL graft replacements remain abnormal for years.

Imaging studies

Acute tendon response

An acute bout of exercise increased the MRI volume and signal in abnormal Achilles tendon. This suggests several critical things: tendon response is rapid, and tendon response is to increase volume (circumference) and water (either bound as part of ground substance or in vessels). This is the earliest form of the reactive response to load proposed in this model.

Normal to reactive, and back

Several studies demonstrate both short-term and long-term changes in the imaging appearance of tendons. Nearly half of normal patellar tendons (with pain) became abnormal (mainly reactive tendinopathy) in the presence of ongoing load over a season of volleyball (high tendon load). A single tendon became hypoechoic, suggesting transition through a reactive tendinopathy to tendon dysrepair/degenerative tendinopathy.

Longitudinal imaging studies have consistently demonstrated that between 10% and 30% of tendons reported as abnormal at baseline become normal at follow-up. This supports the viability of a transition from reactive change back to normal tendon.

Reactive to dysrepair

In a group of young athletes at risk of tendon overload and pathology there was a subgroup with microhypoechoic areas on imaging can be painful. Conversely, two-thirds of tendons degenerative enough to rupture have been reported to be pain-free before rupture.

The source of pain has been associated with neurovascular ingrowth, seen in this model at the late tendon dysrepair/degenerative phase. However, the fact that tendons can be painful or pain-free anywhere in this model suggests another or supplementary cause of pain that has so far proved elusive. The
TREATMENT OF TENDINOPATHY

Clinical treatments directed at effecting change in tendon structure or pathology are considered optimal interventions, but, as pain is often the clinical presentation, a case can be made for concentrating on reduction of pain as a valid outcome. It is evident that pain can occur anywhere in the pathological continuum; interventions that reduce pain and are also appropriate for the stage of pathology should, therefore, be our ideal. Conversely, inappropriate treatments for the stage of pathology (such as “loading up” of a tendon in the proliferative phase of tendinopathy) may increase pain, leading to a poor clinical outcome. Common interventions and their proposed place in this model are summarised in table 2. In an effort to maintain clarity of approach, polymodal interventions, often undertaken in the clinical management of tendinopathy, have not been considered.

Reactive tendinopathy/early tendon dysrepair

Physical treatments

At this stage load management (reduction) will generally allow the tendon time to adapt, the cells to become less reactive and the matrix to resume a more normal structure. Also, a tendon with reduced load is likely to have less pain. Identifying and changing the abusive load may be as simple as allowing a day or two between high or very high tendon loads. Assessment and modification of the intensity, duration, frequency and type of load is the key clinical intervention. This may include identifying the potential for biomechanical overload. Studies show that tendon response in type 1 collagen precursors peaks around 3 days after a single bout of intense exercise, suggesting that time interval for adaptive response is an important factor. Tendon load without energy storage and release, such as cycling or strength-based weight training, can be maintained, as this is less likely to induce further tendon response. Conversely, high-load elastic or eccentric loading, particularly with little recovery time (e.g. on successive days), will tend to aggravate tendons in this stage.

Pharmacotherapies

Non-steroidal anti-inflammatory medications (NSAIDs) have been reported to retard soft tissue healing in a range of tissues. Although pain may be reduced, they have a negative effect on tendon repair. In reactive tendinopathy, this may be a preferred effect, as tenocyte upregulation and excess ground substance expression are apparent in this phase of tendinopathy. Ibuprofen (as well as indomethacin and naproxen sodium) has been shown to inhibit expression of key ground substance proteins responsible for tendon swelling (aggrecan) in in-vitro tendon preparations. Ibuprofen and celecoxib are also reported to have a specific effect in downregulating the cellular response. Ibuprofen may be favoured as it has not been shown to have a detrimental effect on ultimate tendon repair.

Corticosteroids, primarily used to decrease pain, also decrease cell proliferation and protein production and therefore could be used in the reactive painful tendon. Repeated peritendinous corticosteroid has been shown to reduce tendon diameter at 7 and 21 days after injection in tendons. Although peritendinous injection is clinically accepted, it is not known whether peritendon injection induces cell and matrix change within the tendon.

Late tendon dysrepair/degenerative tendinopathy

Physical treatments

Treatments that stimulate cell activity, increase protein production (collagen or ground substance) and restructure the matrix are appropriate for this stage of tendinopathy. Exercise interventions are discussed separately below.

Frictions have been proposed as an effective treatment in tendon injury, and the rationale for their use, based on improving tendon structure, fits into this stage of tendon pathology. They have been shown to increase protein production in animals, but in humans few stringent investigations have been conducted, and the results are variable. Clinically,
Table 2  Clinical and pharmacological treatments placed in the model

<table>
<thead>
<tr>
<th>Stage</th>
<th>Pharmacological management</th>
<th>Physical management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reactive tendonopathy/early tendon dysrepa</td>
<td>Tenocyte inhibitors (ibuprofen, celecoxib, corticosteroids), aggrecan inhibitors (ibuprofen, naproxen sodium, indomethacin)</td>
<td>Load management. Reduction in frequency intensity of tendon load</td>
</tr>
<tr>
<td>ary/late tendon dysrepa/degeneration</td>
<td>Prolotherapy (including blood), aprotinin, sclerosing therapy, glyceryl trinitrate</td>
<td>Exercise with eccentric component, ESWT, frictions, ultrasound</td>
</tr>
</tbody>
</table>

ESWT, extracorporeal shock wave therapy.

compared with exercise, frictions were less effective in reducing pain.39

Extracorporeal shock wave therapy (ESWT) has been shown to have pain-relieving effects in a number of tendons, although ESWT is not consistently shown to be superior to placebo treatment. Studies in animal tendons show variable morphological and mechanical benefits and detriments from this modality, but may be of benefit in this stage of pathology.39

Ultrasound has been shown to increase protein production at a tissue level.39 Similarly to frictions, it is less effective than exercise in treating patellar tendinopathy.39 52

Surgery for chronic painful (presumably degenerative) tendons has produced varied outcomes, with 50–80% of athletes able to return to sport at their previous level.53–55 Although surgical techniques vary considerably, their results are not dissimilar.56 Outcome after surgery was no better than eccentric exercise6 or ESWT66 for patellar tendinopathy. Surgery in non-athletic people produced poorer results than in active people.57

Despite these outcomes, surgery is considered a reasonable option in those who have failed conservative interventions.

Pharmacotherapies

Treatments that stimulate a healing response in the tendon are appropriate for degenerative tendinopathy. The injection of various substances around or into the tendon or the process of injection itself has been proposed to achieve this.

Prolotherapy using glucose and blood injections stimulates a tissue response. Blood injection stimulates cell proliferation and production of vascular endothelial growth factor60, and it has been demonstrated to induce matrix changes. Clinically, blood injections have led to reduced vascularity and decreased tendon diameter on ultrasound.61

Injection itself, regarding the substances injected, has been shown to have a beneficial effect on tendon structure. Multiple tendon biopsies improved structural outcome in degenerative tendons at 1 year compared with an untreated group,62 and injections of active (polidocinol) and placebo (anaesthetic and adrenaline) substances produced similar outcome.63

Aprotinin, a collagenase inhibitor, may preserve collagen in a remodelling matrix. A recent randomised placebo-controlled trial did not show benefits of aprotinin over placebo,60 although earlier studies have shown an effect on pain.60

Sclerosing therapy has repeatedly been shown to be effective in treating pain and improving structure in tendinopathy.66 When compared with placebo, both pain and structural outcomes were significantly better with the sclerosing treatment in both Achilles and patellar tendon.67 Interestingly, the effect on vessels appears to be delayed, with vascularity increasing in the short term after treatment, suggesting that the positive effect on pain may be through chemical neurolysis rather than vascular change.60

Glyceryl trinitrate has been shown to effectively reduce tendon pain in addition to the benefits of eccentric exercise.69–71

It is reported to deliver increased amounts of nitric oxide to the injured tendon, leading to improvement in collagen synthesis, although a recent study has not demonstrated increased tissue levels of NO or benefit from the treatment.72 These studies have not examined the long-term effect of this treatment on tendon structure or tendon vascularity.

PLACING EXERCISE IN THIS MODEL

Exercise, particularly eccentric exercise, has been shown to affect both tendon structure and pain. Eccentric exercise has been shown to increase collagen production in abnormal tendons but not in normal tendons.73 Eccentric exercise has been shown to improve tendon structure in both the short term74 and the longer term75 and decrease tendon vessels.76 Eccentric exercise is an effective pain-relieving treatment, with pain changing in the first 4–6 weeks.77 A meta-analysis reported that eccentric exercise is beneficial for pain, function and return to activity.77

In this model, for athletes in an earlier stage of tendinopathy, who are already loading the tendon in a significant manner, adding exercise (painful or not) may not improve outcome.41 78

This model hypothesises that exercise is a potent stimulus to the already upregulated tendon cells and overstimulates a fundamentally intact, but reactive (or sensitised), matrix. In degenerative tendinopathy, exercise appears to be a positive stimulus for cell activity and matrix restructuring.

In degenerative tendons, exercise-based treatments allow variable levels of pain. The Alfredson eccentric exercise programme suggests that pain during exercise in this stage may be tolerated by the tendon.60 This is supported by Silbernagel et al., whose study in a similar population allowed activity pain of less than 5/10 during activity.71 There was no difference in outcome when compared with a group that just exercised without continuing activity. These studies suggest that exercise that induces pain in the degenerative stage will not affect outcome. If pain in degenerative tendinopathy is mediated by neurovascular structures more than cellular products, as this model suggests, then neurovascular pain appears to be less reactive and tendons would be less irritable in this stage of tendinopathy.

DISCUSSION

We present a simple and succinct model of tendon pathology, which is consistent with the clinical presentations of tendinopathy. The aim of this model is to logically order treatment options for clinicians. Although we have used the term load-induced tendinopathy, we have deliberately not detailed what type of load is responsible. Debate on the relative contribution of tensile, compressive and combined loads is for other fora.

Although these are presented as discrete stages of pathology, it is highly probable that some tendons may have discrete regions that are in different stages at the one time. Examination of tissue, particularly in the latter stages of pathology, often reveals heterogeneous pathology in a single tendon.75 It is possible that a tendon with degenerative change that is acutely overloaded may develop proliferative change in previously normal parts of the tendon. Evaluating these more complex presentations has deliberately not been discussed in this paper to maintain simplicity. Improving capacity to clinically evaluate and treat these more difficult tendons is primarily dependent on accepting the basic model presented.

Research into tendinopathy may also be improved by considering this model. It is possible that the variable response
to tendon treatment in research studies may be explained to some extent through the existence of subpopulations of different pathologies in the investigated cohort. In fact, the most consistent outcomes in research appear to occur when the participants are clearly in one group, such as in Alfredson’s eccentric exercise research on older, presurgical patients.

Very little research has been conducted in early-stage tendinopathy, possibly because of the inherent capacity of these tendons to spontaneously recover, the variability of pain presentation and the difficulties in assembling a sizeable cohort.

The individual factors considered earlier (genes, age, circulating and local cytokine production, sex, biomechanics and body composition) may alter the progression forward or back in the continuum and most are also likely to have an important role in the response to treatment in tendinopathy. For example, some athletes appear completely resistant to tendinopathy despite high loads, and have never been shown to progress into proliferative tendinopathy. Conversely, other athletes sustain tendon ruptures relatively early in their careers, presumably after some degenerative change in the tendon. Identifying athletes at risk of tendon pathology, as well as using this model in treatment, may improve outcomes. Early load management in at-risk athletes may keep them in the early stages of tendon pathology and limit progression.

Time to recovery should be inherent in a clinical model such as this; however, the capacity for tendons to transition up and down between stages makes time estimates for recovery difficult. Overall, tendons respond very slowly, both in improving load capacity and in resolving pain.

CONCLUSIONS

This model explains most clinical presentations and most findings in the tendon literature. It can even encompass primary collagen tearing and some form of inflammation underpinning the cell and matrix response. Emerging mechanisms for injury, complex interactions between the cell and matrix and systemic and local factors (growth factors, cytokines and treatments) will need to be built into this model. The integrity of the model will only be as good as its capacity to withstand additional research. This model now requires scientific and clinical evaluation.

Funding: Jill Cook was funded by a Club Warehouse Visiting Fellowship to the Australian Institute of Sport Physical Therapies department. Club Warehouse had no competing interests.

REFERENCES